Geneva Capital Management LLC decreased its holdings in Bio-Techne Corp (NASDAQ:TECH – Free Report) by 12.6% in the third quarter, HoldingsChannel.com reports. The fund owned 884,168 shares of the biotechnology company’s stock after selling 127,909 shares during the period. Bio-Techne comprises about 1.8% of Geneva Capital Management LLC’s portfolio, making the stock its 19th largest holding. Geneva Capital Management LLC’s holdings in Bio-Techne were worth $64,076,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the stock. Root Financial Partners LLC purchased a new position in Bio-Techne during the 3rd quarter valued at $27,000. Financial Freedom LLC bought a new position in Bio-Techne in the 3rd quarter worth $30,000. Cassaday & Co Wealth Management LLC bought a new position in Bio-Techne in the 1st quarter worth $37,000. Avalon Trust Co bought a new position in Bio-Techne in the 2nd quarter worth $42,000. Finally, Allworth Financial LP purchased a new stake in shares of Bio-Techne in the 2nd quarter worth about $59,000. Institutional investors own 98.95% of the company’s stock.
Wall Street Analyst Weigh In
TECH has been the topic of a number of research reports. Wells Fargo & Company lowered shares of Bio-Techne from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $62.00 to $73.00 in a research note on Thursday, August 13th. Benchmark reiterated a “hold” rating on shares of Bio-Techne in a research report on Wednesday, August 19th. Weiss Ratings raised shares of Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. Zacks Research raised shares of Bio-Techne from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 29th. Finally, Argus lowered shares of Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a report on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $68.92.
View Our Latest Stock Analysis on TECH
Bio-Techne Price Performance
NASDAQ TECH opened at $72.80 on Monday. Bio-Techne Corp has a twelve month low of $43.19 and a twelve month high of $72.88. The firm has a market capitalization of $11.44 billion, a PE ratio of 66.79, a P/E/G ratio of 5.28 and a beta of 1.29. The stock’s 50 day moving average is $72.53 and its 200 day moving average is $63.48.
Bio-Techne (NASDAQ:TECH – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The biotechnology company reported $0.44 earnings per share for the quarter, hitting the consensus estimate of $0.44. The company had revenue of $299.71 million for the quarter, compared to analysts’ expectations of $292.60 million. Bio-Techne had a return on equity of 13.00% and a net margin of 13.95%. On average, research analysts anticipate that Bio-Techne Corp will post 1.75 earnings per share for the current year.
Bio-Techne Cuts Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, November 23rd. Stockholders of record on Friday, November 13th will be issued a dividend of $0.08 per share. This is a drop from Bio-Techne’s previous quarterly dividend of $0.65. The ex-dividend date is Friday, November 13th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.4%. Bio-Techne’s dividend payout ratio (DPR) is presently 29.36%.
About Bio-Techne
Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.
See Also
- Five stocks we like better than Bio-Techne
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH – Free Report).
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
